Pancreatic Cancer Research

ResearcherTongji UniversityActive in the last 2 years

Xiangyu Kong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7515-2613; OpenAlex author ID A5004681856. Sources: OpenAlex.

Their work

Papers
22 (first author 2, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
56
Papers, trials and grants by year

2011: 2 papers · 2012: 2 papers · 2013: 4 papers · 2014: 3 papers · 2015: none · 2016: 2 papers · 2017: 1 paper · 2018: none · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers

Papers 22

  1. Acinar cells modulate the tumor microenvironment through the promotion of M1 macrophage polarization via macrophage endocytosis in pancreatic cancer. Last author DOI 10.1007/s12672-025-02244-5↗
  2. MicroRNA Classifier Based on EUS-FNA for the Early Detection of Occult Liver Metastasis in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/sla.0000000000006755↗
  3. MKLN1-AS promotes pancreatic cancer progression as a crucial downstream mediator of HIF-1α through miR-185-5p/TEAD1 pathway. Last author DOI 10.1007/s10565-024-09863-8↗
  4. Nuclear GRP78 Promotes Metabolic Reprogramming and Therapeutic Resistance in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-23-1143↗
  5. Positive Crosstalk Between Hedgehog and NF-κB Pathways Is Dependent on KRAS Mutation in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2021.652283↗
  6. A novel lncRNA PTTG3P/miR-132/212-3p/FoxM1 feedback loop facilitates tumorigenesis and metastasis of pancreatic cancer. Co-author DOI 10.1038/s41420-020-00360-5↗
  7. VDR signaling inhibits cancer-associated-fibroblasts' release of exosomal miR-10a-5p and limits their supportive effects on pancreatic cancer cells. Last author DOI 10.1136/gutjnl-2018-316627↗
  8. Circulating lncRNA ABHD11-AS1 serves as a biomarker for early pancreatic cancer diagnosis. Co-author DOI 10.7150/jca.32052↗
  9. STK33 Promotes Growth and Progression of Pancreatic Cancer as a Critical Downstream Mediator of HIF1α. First author DOI 10.1158/0008-5472.can-17-0067↗
  10. KLF4-Mediated Suppression of CD44 Signaling Negatively Impacts Pancreatic Cancer Stemness and Metastasis. Co-author DOI 10.1158/0008-5472.can-15-1691↗
  11. Hedgehog Signaling Non-Canonical Activated by Pro-Inflammatory Cytokines in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.7150/jca.15786↗
  12. Down-regulation of microRNA-494 via loss of SMAD4 increases FOXM1 and β-catenin signaling in pancreatic ductal adenocarcinoma cells. Co-author DOI 10.1053/j.gastro.2014.04.048↗
  13. Aberrant MicroRNAs in Pancreatic Cancer: Researches and Clinical Implications. First author DOI 10.1155/2014/386561↗
  14. Chronic Pancreatitis and Pancreatic Cancer. Co-author DOI 10.1159/000365306↗
  15. ABCB2 (TAP1) as the downstream target of SHH signaling enhances pancreatic ductal adenocarcinoma drug resistance. Co-author DOI 10.1016/j.canlet.2013.01.002↗
  16. Aberrant expression miR-196a is associated with abnormal apoptosis, invasion, and proliferation of pancreatic cancer cells. Co-author DOI 10.1097/mpa.0b013e3182962acb↗
  17. Dysregulated expression of FOXM1 isoforms drives progression of pancreatic cancer. Co-author DOI 10.1158/0008-5472.can-12-3859↗
  18. Lamin B1 is a novel therapeutic target of betulinic acid in pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-12-3630↗
  19. Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer. Last author DOI 10.1002/ijc.26422↗
  20. Targeted destruction of the orchestration of the pancreatic stroma and tumor cells in pancreatic cancer cases: molecular basis for therapeutic implications. Co-author DOI 10.1016/j.cytogfr.2012.06.006↗
  21. Detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma patients: miR-196a could be a potential marker for poor prognosis. Co-author DOI 10.1007/s10620-010-1285-3↗
  22. Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis. Co-author DOI 10.1158/0008-5472.can-10-2016↗

Closest collaborators

The 25 strongest of 56 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Fanyang Kong · 6 shared papers, 2014–2024 · strength 0.73
  2. Congjia Ma · 2 shared papers, 2025 · strength 0.50
  3. Keping Xie · 8 shared papers, 2011–2023 · strength 0.47
  4. Zhaoshen Li · 4 shared papers, 2013–2024 · strength 0.41
  5. Zhaoshen Li · 8 shared papers, 2011–2020 · strength 0.38
  6. Yiqi Du · 8 shared papers, 2011–2017 · strength 0.35
  7. Jun Gao · 6 shared papers, 2011–2021 · strength 0.30
  8. Xiulin Hu · 1 shared paper, 2025 · strength 0.28
  9. Kaixuan Wang · 2 shared papers, 2020–2021 · strength 0.23
  10. Zhaoshen Li · 1 shared paper, 2025 · strength 0.21
  11. Xiulin Hu · 1 shared paper, 2025 · strength 0.21
  12. Jiayu Chen · 1 shared paper, 2024 · strength 0.21
  13. Hongyu Wu · 3 shared papers, 2013–2021 · strength 0.21
  14. Yuqiong Wang · 2 shared papers, 2016–2021 · strength 0.17
  15. Tiansuo Zhao · 1 shared paper, 2023 · strength 0.17
  16. Qihui Sun · 1 shared paper, 2023 · strength 0.17
  17. Shaofei Chang · 1 shared paper, 2023 · strength 0.17
  18. Jihui Hao · 1 shared paper, 2023 · strength 0.17
  19. Fang Wei · 1 shared paper, 2023 · strength 0.17
  20. Daoyan Wei · 3 shared papers, 2011–2016 · strength 0.12
  21. Hongwei Xu · 1 shared paper, 2021 · strength 0.12
  22. Tao Sun · 2 shared papers, 2014 · strength 0.12
  23. Lei Li · 1 shared paper, 2019 · strength 0.11
  24. Wenyu Liu · 1 shared paper, 2020 · strength 0.11
  25. Huiqing Zhang · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.